Novo Nordisk seeks fast US review for higher Wegovy dose

27 November 2025

Danish drugmaker Novo Nordisk (NOV: N) has asked the US Food and Drug Administration regulator to assess a stronger 7.2 mg version of its obesity drug Wegovy (semaglutide) under the FDA Commissioner's national priority voucher scheme, potentially clearing the way for a rapid decision. The filing targets adults needing chronic weight-management support.

“Our pipeline is rapidly expanding to meet the needs of people living with obesity, and this submission—under the FDA’s new expedited review program—marks an exciting step forward,” said Anna Windle, senior vice president for clinical development, medical and regulatory affairs at Novo Nordisk.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK